Agenus Inc. will be the first biopharmaceutical company to let investors put their money behind a single drug candidate – the company's PD-1 inhibitor AGEN2034 – by investing in an electronic security that sounds a bit like the digital currency known as bitcoin, but works a little differently.
Lexington, Mass.-based Agenus said on Jan. 29 that it will raise up to $100m through a Biotech Electronic Security Token...






